Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported 18 hours ago - Updated 10 hours ago - 4 reports

Enzalutamide Use Before Chemo Recommended in Europe

The Committee for Medicinal Products for Human Use (CHMP) in Europe has recommended an extension of the use of enzalutamide ( Xtandi , Astellas Pharma Europe Ltd) in the treatment of prostate cancer.The new indication that was recommended for approval ... [Published General Medicine eJournal - 10 hours ago]
First reported Oct 22 2014 - Updated Oct 22 2014 - 2 reports

Astellas Announces Revision of Package Insert in Japan for XTANDI® (enzalutamide) Capsules, a Prostate Cancer Treatment

– Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced the revision of the package insert for the oral androgen receptor signaling inhibitor XTANDI® Capsules 40mg (generic name: enzaluta...Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal ... [Published BioPortfolio - Oct 22 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Forum Post: RE: Degarelix hormone injection, any experience of it?

A group for anyone affected by prostate cancer to get together, ask questions, share experiences and support each other.Degarelix hormone injection, any experience of it?Posted by Calj on18 Oct 2014 8:52 PMHi, my husband has advanced prostate cancer with ... [Published Macmillan Cancer Support - Oct 18 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet

1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-33.2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. ... [Published Cancernetwork.com - Oct 16 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Confirmed: Abiraterone Ups Overall Survival in mCRPC

17-Month Improvement in Survival for Hormone-Sensitive CRPCStéphane Oudard, MD, PhD : Hello. I am Stéphane Oudard, professor of medicine at the Paris Descartes University and chief of the Department of Oncology at the George Pompidou Hospital in Paris, ... [Published General Medicine eJournal - Oct 13 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Approval of enzalutamide pre-chemo a ‘game changer’

The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to one ... [Published Urology Times - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

AR splice variant predicts resistance to PCa treatments

Metastatic castration-resistant prostate cancer patients whose tumors contain the androgen receptor (AR)-V7 splice variant are less likely to respond to enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA) , recent study results indicate.Related - Protein ... [Published Urology Times - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Second agent shows significant benefit in mCRPC pre-chemo

Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 ... [Published Urology Times - Oct 07 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents

Andrew J. RothEmmanuel S. Antonarakis, MBBChAndrogen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to ... [Published OncLive - Oct 04 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 4 reports

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

[News] Biomarker predicts treatment resistance in prostate cancer

A marker detectable through a simple blood test can predict resistance to abiraterone and enzalutamide in men with advanced prostate cancer, a prospective US study shows. In patients with a shortened version of the androgen receptor—AR-V7—which could ... [Published Lancet Oncology - Oct 01 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Dr. Petrylak on the Results of the Phase II STRIDE Study

Daniel P. Petrylak, MD[embedded content] Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE ... [Published OncLive - Sep 27 2014]

Quotes

The new indication that was recommended for approval is used in "the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated."
...the Departments of Radiation and Medical Oncology, respectively, at Thomas Jefferson University in Philadelphia, say the new analysis shows that "men who have received previous docetaxel chemotherapy can be given radium-223 safely and its efficacy will be similar to patients who have not received previous docetaxel treatment."
Original Article: NEXT ARTICLE More From BioPortfolio on "Astellas Announces Revision of Package Insert in Japan for XTANDI® (enzalutamide) Capsules, a Prostate Cancer Treatment"
...The item "Indication" of the package insert has been revised based on the results of the PREVAIL trial, which means the sentence, "The efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy" , has been deleted from the "Precautions regarding indication" item...

More Content

All (123) | News (98) | Reports (0) | Blogs (24) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Enzalutamide Use Before Chemo Recommended in Eu... [Published General Medicine eJournal - 10 hours ago]
Sequencing Radium-223 and Docetaxel in Prostate... [Published General Medicine eJournal - 17 hours ago]
CHMP supports Xtandi label expansion [Published Seeking Alpha - 17 hours ago]
XTANDI™ (Enzalutamide) Capsules Receive Positiv... [Published Yahoo! Finance UK and Ireland - 18 hours ago]
XTANDI™ (Enzalutamide) Capsules Receive Positiv... [Published Business Wire Health News - 18 hours ago]
Astellas Announces Revision of Package Insert i... [Published BioPortfolio - Oct 22 2014]
Astellas Pharma : Announces Revision of Package... [Published 4 Traders - Oct 22 2014]
Forum Post: RE: Degarelix hormone injection, an... [Published Macmillan Cancer Support - Oct 18 2014]
Small-Cell/Neuroendocrine Prostate Cancer: A Gr... [Published Cancernetwork.com - Oct 16 2014]
In Hormone-Naive Metastatic Prostate Cancer, Sh... [Published Cancernetwork.com - Oct 16 2014]
Confirmed: Abiraterone Ups Overall Survival in ... [Published General Medicine eJournal - Oct 13 2014]
Former Dendreon CEO Gold Working on New Cancer ... [Published Xconomy - Oct 13 2014]
Advancing Prostate Cancer Care [Published OncLive - Oct 12 2014]
Cancer Drugs Fund in England: Plugging a Gap in... [Published American Journal of Public Health - Oct 09 2014]
DHEA levels may predict response to advanced PC... [Published Urology Times - Oct 07 2014]
PCa test predicts aggressiveness, influences tr... [Published Urology Times - Oct 07 2014]
Second agent shows significant benefit in mCRPC... [Published Urology Times - Oct 07 2014]
USPSTF PSA grade has ‘minimal’ impact on screening [Published Urology Times - Oct 07 2014]
Data suggest racial disparity in high-risk PCa ... [Published Urology Times - Oct 07 2014]
AR splice variant predicts resistance to PCa tr... [Published Urology Times - Oct 07 2014]
Approval of enzalutamide pre-chemo a ‘game chan... [Published Urology Times - Oct 07 2014]
Consider Medivation for Your Portfolio [Published FOXBusiness.com - Oct 06 2014]
Hopkins Researcher Discusses AR-V7 and Resistan... [Published OncLive - Oct 04 2014]
Vogelzang Disputes âWeakâ Guideline Rating for ... [Published OncLive - Oct 04 2014]
Cancer sufferer calls for equal access to drugs... [Published Newtownabbey Today - Oct 03 2014]
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Cited Articles - Recent - Oct 01 2014]
[News] Biomarker predicts treatment resistance ... [Published Lancet Oncology - Oct 01 2014]
[Corrections] Correction to Lancet Oncol 2014; ... [Published Lancet Oncology - Oct 01 2014]
[Editorial] Emotion-based medicine or evidence-... [Published Lancet Oncology - Oct 01 2014]
XTANDI® (enzalutamide) receives expanded approv... [Published Indianapolis Business Journal - Sep 30 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
XTANDI™ (Enzalutamide) Capsules Receive Positiv... [Published Business Wire Health News - 18 hours ago]
CHERTSEY, England--(BUSINESS WIRE)--Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the Marketing ...
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Cited Articles - Recent - Oct 01 2014]
XTANDI® (enzalutamide) receives expanded approv... [Published PR Newswire: Health - Sep 30 2014]
FLINT, Mich., Sept. 30, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that XTANDI® has been granted an expanded approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant ...
FDA approves Astellas and Medivation's expanded... [Published PBR - News - Sep 11 2014]
The US Food and Drug Administration (FDA) has granted approval to Astellas Pharma and Medivation's expanded use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). ...
Medivation and Astellas win expanded use for pr... [Published Tech Chronicles - Sep 11 2014]
San Francisco pharmaceutical company Medivation, and its partner Astellas Pharma, were celebrating Wednesday after winning federal permission to significantly expand the audience for their prostate cancer drug. The drug, Xtandi or enzalutamide, was first ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.